Fiala, O. Et Al. 2024. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study. Targeted Oncology , vol.19, no.6 , 905-915.

Fiala, O., Massari, F., Basso, U., Giannatempo, P., Grande, E., Buti, S., ... Myint, Z. W.(2024). Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study. Targeted Oncology , vol.19, no.6, 905-915.

Fiala, Ondřej Et Al. "Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study," Targeted Oncology , vol.19, no.6, 905-915, 2024

Fiala, Ondřej Et Al. "Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study." Targeted Oncology , vol.19, no.6, pp.905-915, 2024

Fiala, O. Et Al. (2024) . "Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study." Targeted Oncology , vol.19, no.6, pp.905-915.

@article{article, author={Ondřej Fiala Et Al. }, title={Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study}, journal={Targeted Oncology}, year=2024, pages={905-915} }